Pittsburgh Gut Club: Early Detection of Hepatocellular Carcinoma 11.18.21
Learning Objectives
Review state-of-the-art information on the pathogenesis of gastrointestinal and liver diseases. • Review the latest procedural and diagnostic advancements for gastroenterology practice. • Identify current treatments available for GI diseases and discuss future advancements.
Jorge Marrero, MD, MS, MSHCM: T. Grier Miller Professor of Medicine; Chief, Division of Gastroenterology and Hepatology: University of Pennsylvania Perelman School of Medicine
Disclosure Statement: The following relevant financial relationships were disclosed
Jorge Marrero, MD, MS, MSHCM is a consultant for Glycotest and serves on the Drug Safety Monitoring Board for two AstraZeneca studies.
Robert E Schoen, MD MPH receives Grants/Research support from Freenome and Immunovia Inc.
No other planners, members of the planning committee, speakers, presenters, authors, content reviewers and/or anyone else in a position to control the content of this education activity have relevant financial relationships to disclose.
Accreditation and credit designation
In support of improving patient care, the University of Pittsburgh is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.
Physician (CME)
The University of Pittsburgh School designates this live activity for a maximum of 1.0 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Available Credit
- 1.00 AMA PRA Category 1 Credit™The University of Pittsburgh School of Medicine is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.
- 1.00 Attendance